In Clinical reviews
Follow this topic
Bookmark
Record learning outcomes
Pain is one of the most common reasons people seek healthcare. Estimates suggest that in England alone, up to 34% of the population live with chronic pain — and 12% live with high-impact chronic pain that significantly affects daily life.
Chronic pain always begins at a particular point – and pharmacy is often the first port of call. With more pharmacists qualifying as independent prescribers, community pharmacies increasingly participating in integrated care board activity and pharmacy access requiring no referral, the opportunity for pharmacists to support effective pain management has never been greater.
|
||||||||
Assessment
Good pain management begins with a conversation and initial questions from a pharmacist shape what follows.
For new-onset acute pain, consistent questions will often obtain most of the information needed to make safe decisions about advice and treatment: what happened before the pain began, when it started, how long it has lasted and where it is felt. Pharmacists should ask about the character of the pain, aggravating and relieving factors, medicines already tried, other self-care measures and any previous advice.
A simple numerical or verbal pain scale may help to track change over time, but it should supplement rather than replace conversations. As pain persists, the score increasingly reflects distress and the need for support rather than pain intensity alone.
More important is the effect on function. Someone who cannot sleep, work or walk their dog presents a different clinical picture from someone with mild, intermittent discomfort who can continue their usual activities, even if their pain scores are similar.
Pain is rarely a purely physical experience – mood, stress, sleep quality and social circumstances influence how it is experienced and reported. Open questions such as “How has this been affecting you day-to-day?” may reveal psychological or social contributors that need to be addressed alongside the pain and are unlikely in themselves to respond to analgesics. These so-called yellow flags (see Table 1) can indicate a greater risk of a longer-term pain problem.
| Table 1: Yellow flags – psychological and social factors affecting pain | |
| Attitudes | Behaviours |
|
|
| Compensation issues | Family |
|
|
| Disability | Emotions |
|
|
| Work | |
|
|
Patient factors
Patient factors can also shape treatment choices:
Age and frailty
- Falls risk with sedating analgesics, altered pharmacokinetics and lower threshold for NSAID-, opioid- and gabapentinoid-related harm in older and frailer people
- Opioid dose should be age-banded with lower doses for increasing age
Comorbidity examples
- Cardiovascular and/or renal disease and NSAIDs
- Hepatic disease and appropriate paracetamol dosing
- Diabetes and neuropathic pain overlap
- COPD and/or obesity and gabapentinoids
Pregnancy and breastfeeding
- Paracetamol normally first-line
- NSAIDs generally avoided, particularly from 20 weeks’ gestation
- Caution with codeine and other opioids
Renal and hepatic impairment
- Dose adjustment or avoidance of NSAIDs, opioids and gabapentinoids
Polypharmacy and interaction risk
- Anticoagulants and NSAIDs
- Sedative load with opioids, gabapentinoids and benzodiazepines
- Serotonergic interactions with multiple antidepressants and opioids including tramadol
Previous treatment response
- What has worked; what has not
- Ineffective dose, poor tolerance or genuine lack of efficacy are different problems.
Pharmacists should also assess for red flags. Most people presenting with pain in community pharmacy will have benign, self-limiting conditions, but some need urgent escalation. If no red flags are present and onward referral is not required, the decision then is how best to support pain management in pharmacy.
| Table 2: Red flags warranting urgent referral |
|
Acute pain
Musculoskeletal pain, headache, dental pain, minor injury and period pain account for many acute pain presentations in community pharmacy, most of which can be managed there.
Non-pharmacological measures are important but easily overlooked. For most musculoskeletal pain, relative rest can be advised without prolonged immobilisation and early, gentle movement encouraged. Ice is effective during the first 48 hours after acute injury, followed by warmth for ongoing muscular tension and ice after exercise or movement.
Sleep and activity advice is relevant to all pain presentations, and these measures may be sufficient for tension headache and low-grade musculoskeletal pain.
Pharmacological options should be based on safety for the individual, effectiveness and route of administration, in that order:
- Paracetamol remains a reasonable option for acute pain. However, evidence of effectiveness is limited in headache, migraine and period pain
- Topical analgesics offer a lower-risk alternative for localised musculoskeletal pain, particularly when systemic exposure is a concern
- Oral NSAIDs are effective for musculoskeletal, dental and period pain, but have GI, renal and cardiovascular risks. These should be considered particularly in older people and those taking other nephrotoxic or ulcerogenic medicines
- Short-term opioids may occasionally be appropriately used for acute, severe pain – for example, post-injury or surgery, or when paracetamol and/or an NSAID alone is inadequate. Treatment should be started with an explicit end point and the risk of dependence discussed (possible even after only a few days of use)
- Combination analgesics such as co-codamol are not recommended for acute or chronic pain unless the effectiveness of both components has been demonstrated. They are difficult to titrate or taper and may expose people to analgesics they do not need.
Formulation considerations
Formulation also matters. Tablets suit most adults, but liquids, orodispersible formulations or soluble preparations are options for people with swallowing difficulties.
Topical options can improve adherence where oral routes are not tolerated or side-effects are problematic. Transdermal opioids should only be used where an opioid has been shown to be at least partly beneficial at reducing pain intensity and improving function. They are difficult to titrate and taper, and so are not indicated at all for acute, new-onset or changing levels of pain.
A brief conversation about what the person will take reliably is often more valuable than identifying the ‘best’ option on paper. Many presentations can be managed in community pharmacy using established local pathways rather than defaulting to informal advice. This supports patient confidence and demonstrates what pharmacy teams can safely and effectively provide.
| Table 3: Quick reference examples for common acute presentations | ||
| Presentation | First-line | Consider next if... |
| Tension headache | Paracetamol or NSAID | Migraine features – consider triptan or refer if new/atypical |
| Muscle strain/sprain | Topical NSAID + movement advice | Poor response – short course of oral NSAID if not contraindicated |
| Dental pain | NSAID (unless contraindicated) ± paracetamol | Awaiting dental review – combination analgesic short-term |
| Period pain | NSAID | If paracetamol contraindicated – consider hormonal options (prescriber referral) |
| Minor injury | Ice, rest, paracetamol/NSAID | Suspected fracture or red flag – refer urgently |
Chronic pain
Chronic pain requires a different approach and it is worth making that shift explicit to patients. The goal is not to eliminate pain completely but to improve function and quality of life within realistic individual limits. When communicated sensitively, this reframing can reduce distress and challenge the assumption that analgesics are the only option.
Osteoarthritis, chronic low back pain, fibromyalgia and neuropathic pain are common presentations. People may be taking long-term analgesic regimens that have not been formally reviewed for some time, creating an opportunity for a medicines optimisation conversation.
Patients should be asked whether the regimen still provides benefit, whether doses have increased without review, and whether opioids or gabapentinoids continue to deliver meaningful functional improvement. Pharmacists should also consider what has changed in the person. An analgesic dose may be unchanged, but a new condition or non-analgesic medicine may make existing treatment more harmful than before.
Analgesic stewardship should be central to pharmacists’ role in managing pain: indication, dose and ongoing need should be checked, and non-judgemental conversations about tapering introduced early where appropriate. Long-term opioids and gabapentinoids are associated with established harms in non-cancer pain – including dependence and hyperalgesia – and there is limited evidence of sustained benefit.
Non-drug strategies are essential in chronic pain. Physical activity, pacing and psychologically informed approaches, including pain management programmes, can be beneficial. Social prescribing may also improve outcomes.
The same considerations for acute pain apply with emphasis on:
- Long-term NSAID risks
- Use the lowest effective dose for the shortest duration
- Use gastroprotection where indicated
- Neuropathic pain – this typically responds poorly to standard analgesics
- A screening tools such as S-LANSS (see the online version of this article for the URL) can be used, rather than adding in medicines just because standard analgesics “are not working”
- Regular monitoring – particularly for anyone on long-term opioids, gabapentinoids and combinations of analgesics
- Be alert to dose increases and new medicines being added, whether or not they are prescribed for pain.
Prescribing considerations
Independent prescribers have more options. In acute pain, this may include initiating a short course of a POM analgesic, prescribing a triptan for an established migraine, or adjusting an existing prescription.
In chronic pain, it may involve screening for neuropathic pain and initiating a medicine, reviewing and adjusting long-term opioid therapy, or agreeing a taper through shared decision-making with the patient that previously required a GP appointment to authorise.
This additional scope comes with greater responsibility – safe prescribing requires pharmacists to work within their competence. Controlled drugs demand accurate record keeping and review of shared care or GP records where accessible, and vigilance for patterns that may suggest misuse or diversion.
Clear communication with the patient’s GP or usual prescriber helps prevent fragmented records and attempts to obtain medicines from different professionals. Collaboration, clear referral letters, shared documentation and defined pathways with local pain clinics and physiotherapy services matter as much as clinical decision-making, whether or not the pharmacist is prescribing.
Independent prescribing extends what is possible but does not remove the need for referral when pain falls outside a pharmacist’s competence or experience. Specialist input should be sought promptly when there is diagnostic uncertainty or a need for pain clinic, rheumatology or neurology support. The value of prescribing status lies as much in recognising this boundary as in knowing what can be managed before reaching it.
Communicating well and safety-netting
Even a sound clinical decision can be undermined by poor communication. Being explicit about likely outcomes and risks, such as the likelihood of pain stopping or the possibility that the pain will persist, and the risk of dependence with opioids and gabapentinoids, is kinder in the long run than vague reassurance. It supports genuine shared decision-making rather than a person just doing what they are told.
Safety-netting should be specific rather than generic. Give a clear timeframe – such as “if this has not settled within five days” – and identify symptoms that require earlier review. This helps community management of pain feel safe for both patient and pharmacist but is not a substitute for proper follow-up.
When and where to refer
Referral is part of community pain management – not a failure of it – and pharmacists should understand both routine and urgent pathways. Red flags, serious pathology or safeguarding concerns may require same-day GP assessment or emergency care, while pain that persists or worsens despite optimised self-care and OTC/prescribed treatment may need routine GP or specialist review.
Complex comorbidity that limits safe options, or mental health concerns including pain-related distress, may also require support that community pharmacy cannot provide.
Signposting is also underused. NHS 111 and local urgent care services can support same-day concerns, while condition-specific charities such as Arthritis UK may offer peer support and self-management resources. Local physiotherapy or musculoskeletal services may accept self-referrals.
Many areas also have social prescribing link workers or health coaches attached to primary care networks who may accept direct referrals. Pharmacists may not be able to resolve isolation, housing stress or financial hardship, but an effective referral can help. Keeping accurate local information to hand makes signposting genuinely useful rather than a way to end the conversation.
| Table 4: Decision checklist for pharmacy management or referral |
|
Conclusion
The role of community pharmacists in pain management extends well beyond a ‘sell or send to GP’ interaction. A structured assessment, appropriate use of self-care, OTC and prescribed options, and confidence about referral enable pharmacists – whether prescribers or not – to provide accessible and safe care.
The skill lies not in having every answer, but asking the right questions, choosing options that are appropriate for the individual, and recognising when someone needs more than the pharmacy can offer.